Vistagen Therapeutics Statistics
Total Valuation
VTGN has a market cap or net worth of $171.02 million. The enterprise value is $95.71 million.
Important Dates
The last earnings date was Thursday, November 13, 2025, after market close.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
VTGN has 39.50 million shares outstanding. The number of shares has increased by 7.22% in one year.
| Current Share Class | 39.50M |
| Shares Outstanding | 39.50M |
| Shares Change (YoY) | +7.22% |
| Shares Change (QoQ) | +11.96% |
| Owned by Insiders (%) | 0.26% |
| Owned by Institutions (%) | 33.73% |
| Float | 29.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 195.14 |
| Forward PS | n/a |
| PB Ratio | 2.54 |
| P/TBV Ratio | 2.58 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 132.74 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.79, with a Debt / Equity ratio of 0.03.
| Current Ratio | 5.79 |
| Quick Ratio | 5.66 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -78.13% and return on invested capital (ROIC) is -50.22%.
| Return on Equity (ROE) | -78.13% |
| Return on Assets (ROA) | -44.62% |
| Return on Invested Capital (ROIC) | -50.22% |
| Return on Capital Employed (ROCE) | -97.31% |
| Revenue Per Employee | $12,649 |
| Profits Per Employee | -$1.09M |
| Employee Count | 57 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +65.27% in the last 52 weeks. The beta is 0.56, so VTGN's price volatility has been lower than the market average.
| Beta (5Y) | 0.56 |
| 52-Week Price Change | +65.27% |
| 50-Day Moving Average | 4.08 |
| 200-Day Moving Average | 2.99 |
| Relative Strength Index (RSI) | 51.98 |
| Average Volume (20 Days) | 900,082 |
Short Selling Information
The latest short interest is 1.52 million, so 3.84% of the outstanding shares have been sold short.
| Short Interest | 1.52M |
| Short Previous Month | 1.36M |
| Short % of Shares Out | 3.84% |
| Short % of Float | 5.20% |
| Short Ratio (days to cover) | 3.31 |
Income Statement
In the last 12 months, VTGN had revenue of $721,000 and -$62.24 million in losses. Loss per share was -$1.92.
| Revenue | 721,000 |
| Gross Profit | 721,000 |
| Operating Income | -65.47M |
| Pretax Income | -62.24M |
| Net Income | -62.24M |
| EBITDA | -65.30M |
| EBIT | -65.47M |
| Loss Per Share | -$1.92 |
Full Income StatementBalance Sheet
The company has $77.18 million in cash and $1.87 million in debt, giving a net cash position of $75.31 million or $1.91 per share.
| Cash & Cash Equivalents | 77.18M |
| Total Debt | 1.87M |
| Net Cash | 75.31M |
| Net Cash Per Share | $1.91 |
| Equity (Book Value) | 66.34M |
| Book Value Per Share | 1.71 |
| Working Capital | 65.29M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$52.95 million and capital expenditures -$213,000, giving a free cash flow of -$53.16 million.
| Operating Cash Flow | -52.95M |
| Capital Expenditures | -213,000 |
| Free Cash Flow | -53.16M |
| FCF Per Share | -$1.35 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -9,080.86% |
| Pretax Margin | -8,631.90% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |